














PRN OPINION PAPER

Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy

Scott A. Coon Pharm.D.¹  | Lucas G. Hill Pharm.D.²  |
Robert W. Hutchison Pharm.D.³  | Lindsay M. Arnold Pharm.D.⁴  |
Jennie B. Jarrett Pharm.D., MMedEd, FCCP⁵  | Anne R. Ottney Pharm.D.⁶  |
Alvin B. Oung Pharm.D.⁷  | Nathan A. Painter Pharm.D.⁸  |
Michael A. Smith Pharm.D.⁹  | Paul M. Stranges Pharm.D.⁵  |
Tran H. Tran Pharm.D.¹⁰  | Amanda R. McFee Winans Pharm.D.¹¹  |
Jeffrey P. Bratberg Pharm.D.¹² 

¹Department of Pharmacotherapeutics & Clinical Research, University of South Florida, Taneja College of Pharmacy, Morsani College of Medicine, Tampa, Florida

²Division of Pharmacy Practice, The University of Texas at Austin College of Pharmacy, Austin, Texas

³Department of Pharmacy Practice, Texas A&M Irma Lerma Rangel College of Pharmacy, Round Rock, Texas

⁴Department of Pharmacy Services, St. Elizabeth's Medical Center, Brighton, Massachusetts

⁵Department of Pharmacy Practice, University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois

⁶Department of Pharmacy Practice, Ferris State University, College of Pharmacy, Big Rapids, Michigan

⁷Department of Pharmacy Practice, University of Wyoming School of Pharmacy, Laramie, Wyoming

⁸Division of Clinical Pharmacy, University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, California

⁹Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan

¹⁰Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Downers Grove, Illinois

¹¹Section of Clinical Pharmacy, Department of Pharmaceutical Care Services, Bassett Medical Center, Cooperstown, New York

¹²Department of Pharmacy Practice, University of Rhode Island College of Pharmacy, Kingston, Rhode Island

Correspondence

Scott A. Coon, Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy, University of South Florida, 12901 Bruce B. Downs Blvd., MDC 30, Tampa, FL 33612.
Email: scoon1@usf.edu

Abstract

The opioid crisis represents one of the largest failures of our current health care system as it continues to claim lives at an unprecedented rate and has caused a devastating range of preventable morbidity. Although the availability of highly potent synthetic opioids has amplified the urgency of the crisis for patients and communities, this problem has evolved over several decades. Pharmacists are in a position to offer many potential solutions due to their widespread accessibility, extensive drug knowledge, and integration into various health care settings. This opinion paper challenges the status quo by calling on all pharmacists to embrace evidence-based opioid stewardship and harm reduction practices, contribute to the medical management of

opioid use disorder, and address the misconceptions and prejudices that serve as barriers to effective, compassionate patient care. Regardless of practice setting or available resources, pharmacists can take deliberate and impactful steps to address the opioid crisis. Some pharmacists may be positioned to implement innovative and far-reaching pharmacist-led clinical services, while others may simply begin with careful consideration of the language they use when speaking to and about patients with substance use disorders. To optimize patient outcomes, the ineffective laws, regulations, and policies that negatively impact pain and addiction care must be addressed so that evidence-based solutions can be widely disseminated. Pharmacists must aggressively advocate for the removal of barriers preventing high-level clinical practice or policies that perpetuate patient harm and abandonment. Finally, there must be support for continued research on pain and opioid use disorder treatments and services, as well as the impacts of harm reduction practices and pharmacist-led clinical services, so that resources can be allocated effectively.

KEYWORDS

harm reduction, opioid epidemic, opioid-related disorders, pharmacists, social stigma

1 | INTRODUCTION

Clinical Scenario 1: A woman with chronic low back pain and a 15-year history of daily opioid use is referred to the clinical pharmacist to develop an opioid tapering plan. The provider wants to reduce the patient's daily morphine milligram equivalents (MME) to below 90 mg as quickly as possible—"then we will see if we can stop it completely because opioids don't even help with back pain...plus the director flagged my average MMEs as being too high this quarter." The provider requests that the clinical pharmacist meet with the patient to complete her care plan for the day, including urine drug screening, prescription monitoring program evaluation, and naloxone education.

A series of five hypothetical clinical scenarios likely to be encountered by a pharmacist are offered with each major section. See the Clinical Scenario Considerations for guidance on each scenario.

Joint Commission and American Pain Society championed the effort to make pain "visible," so that it could be managed effectively.² Pain was labeled as the "fifth vital sign," and opioids became a quick solution to short- and long-term pain needs. At the time, opioids for therapeutic indications were thought to rarely lead to addiction. A substantial increase in opioid prescribing ensued, peaking in 2010.^{3,4} The incidence of opioid-related fatal overdoses⁵ and the prevalence of opioid use disorder (OUD) also increased steadily during this time frame.⁶ By 2010, drug overdose was the leading cause of injury death in the United States and opioids were involved in a majority of these fatalities.⁷ The staggering rate of fatal opioid overdoses has led to a range of responses from regulatory bodies.

The release of the Centers for Disease Control and Prevention (CDC)'s *Guideline for Prescribing Opioids for Chronic Pain* in 2016 represented a landmark moment in the effort to address rising rates of opioid-related harm in the United States.⁸ The guideline contains 12 broad recommendations aimed at enhancing opioid prescribing safety among primary care providers. Importantly, these recommendations were offered with caveats for patient-specific implementation and an implementation guide was later issued⁹ to assist with the integration of guideline principles into practice. Before and after issuance of this guideline, many states adopted laws and regulations to restrict opioid prescribing and dispensing.¹⁰⁻¹² These and other restrictions have resulted in many unintended consequences, such as increased use of nonregulated and nonprescription opioids, untreated OUD, suboptimal chronic pain management, poor quality of life, involuntary opioid tapering and discontinuation, and suicide.¹³⁻¹⁶ Concerns relating to misapplication of the CDC guideline prompted its authors to publish a commentary reiterating that these guidelines should not be strictly implemented at the population level.¹⁷

1.1 | Shifting landscape of opioid-related harm

Situations resembling Clinical Scenario 1 are becoming increasingly common and shine a spotlight on how far the pendulum has swung in opioid prescribing and pain management.¹ The 1990s to 2000s were a time of increased pain awareness, when organizations such as The


The CDC estimates there were 46 802 fatal overdoses involving opioids in 2018.¹⁸ Until recently, the rate of unintentional fatal opioid overdoses had been increasing, though currently only the rate of fatal overdose from synthetic opioids (eg, illegally manufactured fentanyl) continues to climb.^{5,18,19} Clinicians are now being advised to consider screening all adults for illegal drug use,²⁰ limit opioid prescribing for only chronic, severe and/or unrelenting pain syndromes, co-prescribe naloxone, prioritize life-saving medications for OUD (MOUD), and refer patients to services that enhance their long-term recovery.⁸ This is a dramatic and rapid change for health care providers and their patients. Pharmacists must rise to the challenge at hand, lending their drug and disease management expertise to health care teams across the spectrum of care to prevent avoidable deaths and other morbidity, while continuing to improve care for patients with acute and chronic pain.

1.2 | Pharmacist's role in advancing evidence-based solutions

The optimal approach for achieving positive patient outcomes is through a comprehensive model of opioid stewardship and increased access to harm reduction resources and evidence-based MOUD. This approach must also include compassionate and comprehensive treatment of pain. The Joint Commission has employed pain assessment and management standards, including specific elements of performance

surrounding safe opioid prescribing. While opioid stewardship is not required by The Joint Commission, it is an inferred recommendation from several regulatory agencies. Opioid stewardship can be universally described as “coordinated interventions designed to improve, monitor, and evaluate the use of opioids in order to support and protect human health”²¹; however, a standardized definition currently is lacking. While several governmental and regulatory agencies, including The Joint Commission, do not delineate the specific role of the pharmacist, most advocate that pharmacists play an integral role on opioid stewardship teams. Pharmacists ensure safe and effective opioid therapy, implement harm reduction strategies, reduce stigma associated with opioid use and OUD, facilitate medication-based addiction treatment, optimize pain management, perform patient and provider education, and advocate for broader pharmacist privileges to co-manage OUD and pain management pharmacotherapy.^{21,22} See Figure 1 for examples of pharmacist activities.

It is crucial that opioid stewardship programs do not focus solely on supply reduction strategies, as harm reduction strategies are more effective at preventing opioid-related mortality and morbidity.²³ Harm reduction strategies prioritize the minimization of negative consequences associated with a risky behavior, such as illegal drug use, rather than seeking to force abstinence from that behavior.²⁴ These interventions often target patients at highest risk for substance-related harm, such as those with current or recent illegal substance use and intravenous drug use. It is vitally important that pharmacists recognize the unintended consequences of supply reduction strategies applied in



Harm reduction
<ul style="list-style-type: none"> • Providing sterile injection education and distribution of injection equipment • Educating on overdose reversal and naloxone distribution • Providing fentanyl testing strips and educating on safe use of unknown illegal opioids • Screening for HCV and HIV, administering immunizations, and recommending pre-exposure prophylaxis • Educating on safe opioid storage and disposal • Facilitating wound care and triage
Opioid stewardship
<ul style="list-style-type: none"> • Developing and implementing evidence-based opioid treatment plans • Developing opioid order sets, prescribing protocols, and guidelines • Initiating and modifying non-pharmacologic and non-opioid therapies • Conducting prospective and retrospective case reviews • Developing and implementing opioid taper plans • Evaluating high-risk drug/disease combinations (e.g. opioid-benzodiazepine) • Developing and implementing controlled substance agreements • Interpreting qualitative and quantitative toxicology test results • Monitoring for opioid misuse by patients and healthcare professionals
Opioid use disorder treatment
<ul style="list-style-type: none"> • Initiating and modifying pharmacotherapy (e.g. buprenorphine and naltrexone) • Monitoring and follow-up (e.g. observed daily dosing, toxicology results) • Facilitating adjunct services (e.g. mental health, HCV and HIV therapy) and wrap-around patient resources (e.g. transportation, housing, employment) • Addressing stigma and negative attitudes towards treatment and PWUD • Advocating for patients and the expanded role of the pharmacist in treatment

FIGURE 1 Pharmacist involvement in harm reduction, opioid stewardship, and opioid use disorder treatment. This figure shows activities and services in which pharmacists may be involved and is not intended to be all inclusive. Many activities are subject to state and federal law, which pharmacists must know and adhere to. HCV, hepatitis C virus; HIV, human immunodeficiency virus; PWUD, people who use drugs. All images are licensed under Creative Commons BY 2.0

isolation and become outspoken advocates for harm reduction strategies.

Pharmacists must also work to enhance identification of patients with OUD and facilitate access to evidence-based MOUD. Although OUD is largely managed by addiction specialists and primary care physicians (PCP), the available supply of professionals in these disciplines is insufficient. Using data from the Substance Abuse and Mental Health Services Administration (SAMHSA), 96% of states had insufficient capacity to meet treatment demands.²⁵ Pharmacists play a major role in meeting these demands by actively treating OUD and engaging patients with OUD to improve outcomes.²⁶ Additionally, pharmacists can help eliminate treatment barriers including insurance coverage, restrictive state and federal policies, and treatment stigma, which is prevalent among patients, their family members, and health care workers.

The following opinion paper is intended to provide insight into the current opioid crisis and offer pragmatic steps for pharmacists to become involved in opioid stewardship, harm reduction, and the management of OUD. Furthermore, this paper will discuss the numerous barriers to care and identify opportunities for continued pharmacist advocacy and training. Although this paper represents the opinion of the Ambulatory Care and Adult Medicine Practice and Research Networks of the American College of Clinical Pharmacy (ACCP), it is not considered an official ACCP commentary, guideline, or statement of position or policy.

2 | HARM REDUCTION

Clinical Scenario 2: The clinical pharmacist enters the examination room and can immediately see the patient is anxious about the impending discussion. "It's a pleasure to meet you. Your doctor asked me to speak with you today about some of the risks associated with your opioid pain medication." She replies defensively, "I've been taking the same one for 15 years. I'm not a junkie. I need this medicine." The clinical pharmacist adjusts his approach. "I understand that your medicine is important to you, and I don't want to take it away or change your dose today. Is it ok if we talk about a new medicine that can help keep you safe while you continue taking opioids? It's called naloxone."

2.1 | Prioritizing harm reduction

According to the Harm Reduction Coalition, "Harm reduction is a set of practical strategies and ideas aimed at reducing negative consequences associated with drug use. Harm Reduction is also a

movement for social justice built on a belief in, and respect for, the rights of people who use drugs."²⁴ Available evidence indicates that harm reduction interventions should be the first priority for pharmacists seeking to address the current crisis of opioid-related morbidity and mortality in the United States.²³

2.2 | Overdose education and naloxone distribution

Naloxone is a life-saving medication when administered for the reversal of acute opioid overdose. The medication antagonizes opioids present in the central nervous system by strongly binding opioid receptors and temporarily displacing receptor-bound opioids for 1-2 hours.²⁷ Currently, naloxone is available in several formulations appropriate for administration by a layperson, such as intranasal or intramuscular routes.²⁸ Two recently approved products using each of these routes of administration have been shown to have advantages regarding ease of use and may thus be preferable when increased cost is not a barrier.²⁹⁻³² When used, naloxone can restore normal respiration and consciousness in the overdose victim.¹¹ Improving access to naloxone has become a national priority endorsed by the Surgeon General, and every state has enacted at least one naloxone access law (NAL) to achieve this goal.^{33,34} Community-based models for take-home naloxone through harm reduction coalitions, substance use disorder (SUD) treatment programs, and syringe service programs (SSP), also known as syringe exchange programs, have been in place for decades in the United States with impressive results.^{12,35} However, SSPs are illegal in 15 states, and 93% of counties deemed high risk for an outbreak of human immunodeficiency virus (HIV) or hepatitis C virus (HCV) have no SSP. They are particularly rare in rural areas, highlighting the importance of rural pharmacists in enhancing access to naloxone and other harm reduction supplies.³⁶

The 2016 *Guideline for Prescribing Opioids for Chronic Pain* recommends that clinicians offer patients naloxone when risk factors for opioid overdose are present (eg, history of overdose, SUD, use of high-dose opioid analgesics, or concurrent benzodiazepine).⁸ Co-prescribing naloxone to patients with chronic pain receiving opioids in primary care settings was associated with a 47% reduction in opioid-related emergency department visits in one observational trial, and multiple studies have demonstrated that patients are receptive to overdose education and there is a high willingness to prescribe naloxone in primary care settings.^{34,37,38} Despite this evidence of efficacy, multiple studies have demonstrated that the majority of patients at high risk for opioid-related overdose have not been dispensed naloxone.^{39,40} Multiple contributing factors to suboptimal naloxone co-prescribing have been identified amongst prescribers, including a lack of knowledge regarding how to prescribe it, to whom it should be prescribed, and how to educate patients about its use.³⁸ Legislative mandates which require naloxone co-prescribing for certain high-risk patient populations have been associated with a substantial increase in naloxone dispensing, indicating legislative or regulatory action may be necessary to achieve and sustain substantial increases.^{41,42} The

Food and Drug Administration (FDA) has recommended that all MOUD and opioid manufacturers include naloxone in their prescribing information to be discussed with patients.⁴³

State-level enactment of a NAL is associated with increased naloxone dispensing and reductions in fatal overdose.⁴⁴⁻⁴⁶ The specific elements of state NALs vary with inconsistent inclusion of legal protections for overdose victims and witnesses who seek emergency medical services, as well as rare inclusion of naloxone co-prescribing mandates. However, NALs tend to include three core components: (a) expanded authority for pharmacists to distribute naloxone; (b) allowance for third-party prescribing to individuals who may witness an overdose; and (c) broad liability protection for health care professionals and overdose responders. State approaches to expand pharmacists' authority to distribute naloxone may have an impact on population-level outcomes as well. A recent analysis found that granting pharmacists "direct authority" to distribute naloxone (ie, dispensing naloxone without a prescription) is associated with a 27% to 34% reduction in overdose mortality while granting "indirect authority" (eg, statewide protocol or standing order) was not associated with a significant reduction.⁴⁷ However, the true impact of increased pharmacist autonomy through direct authority NALs remains unclear. Mounting evidence indicates that pharmacists are not taking advantage of authority under state NALs and do not possess sufficient knowledge to effectively identify high-risk patients and provide overdose education.⁴⁸⁻⁵¹ Similar findings are seen in other countries such as Australia, where naloxone is available behind-the-counter.⁵² Academic detailing is one viable solution for improving pharmacist knowledge about naloxone and the likelihood that naloxone will be stocked and dispensed in community pharmacies.⁵³⁻⁵⁶ Larger, collaborative initiatives such as the ONE Rx program in North Dakota offer a promising framework for expanding community pharmacist screening for opioid misuse and potential for overdose, but is still limited by low "reach" (number of patients screened) and "implementation" (number of pharmacies completing at least five screenings) when evaluated under the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) model.⁵⁷

A rapidly growing body of research explores the role of pharmacists in naloxone distribution and education across numerous practice settings.^{34,55-60} Pharmacist involvement in these programs has ranged from program development and provider training to patient identification and education. Pharmacists in all health care settings should establish automatic protocols to identify patients at risk for overdose and proactively offer naloxone with comprehensive education to patients as well as their friends, family, and caregivers, who may be responsible for administering naloxone during an emergency.

2.3 | Syringe access and injection safety

Persons who inject drugs (PWID) are at risk for serious infections including HIV, hepatitis B virus (HBV), HCV, and severe bacterial infections such as endocarditis. Hospitalizations for infections in PWID in the United States increased dramatically from 301 707 (2002) to 520 275 (2012), with related inpatient charges increasing to \$15 billion.⁶¹ Access

to sterile syringes has the potential to curb these increasing rates of preventable illness and expense. Pharmacists play a key role in maintaining and expanding access to sterile syringes, providing education about safe injection technique, and assuring safe syringe disposal.⁶²

SSP are typically community-based prevention programs providing access to sterile syringes, drug preparation equipment, and safe disposal at no cost to PWID.^{63,64} The range of services provided through SSPs may be limited to only sterile syringe access or include a variety of additional harm reduction and OUD services. These programs have long been recognized as a means for decreasing transmission of HIV, HBV, and HCV.^{65,66} Following full implementation of a structured SSP in New York, investigators reported a 29% decrease in HCV prevalence ($P = .034$) and a 40% decrease in HIV and HCV coinfection prevalence in PWID ($P < .01$).⁶⁶ Following introduction of the first SSP pilot in Florida in 2016, there was a 49% decrease in syringes found in public areas.⁶⁷ Importantly, these data can stimulate swift changes to state syringe laws, such as the passage of Florida's Infectious Disease Elimination Act in 2019 following these pilot data. Also, SSPs are increasingly recognized as an opportunity to engage patients with SUDs who otherwise may not be ready to participate in treatment discussions.^{63,65} The US Surgeon General supports SSPs as part of a set of comprehensive morbidity and mortality-reducing interventions for the opioid crisis.⁶⁸ In addition to syringe access, many PWID are unaware of their eligibility for pre-exposure prophylaxis, which has also been shown to significantly reduce HIV transmission.^{69,70} Community pharmacies offer an ideal venue for syringe exchange and other services for PWID, as they already offer syringes and wound care products and can offer related screening, treatment, and educational services by pharmacists and interns.⁷¹ In states such as Minnesota, where syringe access legislation promotes pharmacy dispensing of sterile injection equipment, over 60% of community pharmacists surveyed were comfortable dispensing syringes from their pharmacy.⁵¹ Unfortunately, in many states, paraphernalia and syringe access laws, as well as stigmatizing business policies, severely limit pharmacists from engaging PWID to the fullest extent possible.

2.4 | Medication storage, security, and disposal

Providing counseling on (a) storage of opioids in a locked container; (b) keeping opioids in their original package; (c) keeping opioids out of children's reach; (d) not sharing medication with others; and (e) safely disposing of unused pills are all key pharmacist roles. Appropriate disposal of unused prescription opioids is crucial for reducing harms associated with both unintentional ingestion and suicide. Improving patient knowledge about proper disposal can mitigate unauthorized access to medications and reduce unintentional ingestions among children.⁷² The primary source for prescription opioids for nonmedical purposes is family and friends (Figure 2).^{73,74}

Pharmacist-led initiatives to improve patient knowledge about opioid disposal can make a significant difference. Providing patients information on drug disposal programs at local pharmacies along with a small incentive, such as a coupon, was associated with a 22%




FIGURE 2 Sources of prescription pain relievers for nonmedical use. Data are from the Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration 2018 National Survey on Drug Use and Health.⁷³ Percentages are approximate as values were rounded to the nearest whole number

increase in the proportion of patients disposing their unused opioids following dental procedures.⁷⁵ Drug disposal education is becoming more prevalent, but there are opportunities for improvement. In a recent analysis, approximately 61% of survey participants stated they received counseling on medication disposal from a health care professional within the past year which increased the likelihood for medication disposal by 67%.⁷⁶ However, most of this education was not being done by pharmacists, who were identified as the source for this counseling only 21% of the time.⁷⁶ Highly regulated and advertised medication drop boxes and drug takeback days are also effective, though low-cost and easily implemented educational interventions (eg, informational brochures) seem to have a significant impact on disposal rates as well.⁷⁷⁻⁷⁹

Guidelines developed by the US Office of National Drug Control Policy, and Environmental Protection Agency for the disposal of household pharmaceuticals include (in order of preference): (a) use a drug take-back event or drop box; (b) dispose in household trash after mixing the medication with an unpalatable substance (eg, free manufacturer provided charcoal pouches, commercially available drug disposal kits, cat litter, or coffee grounds) and placing the mixture in a sealed container; and (c) flush the unwanted medicine down the toilet if the drug label specifically instructs you to do so (40 C.F.R. Sect. 266.505).⁸⁰ Medication mail-back envelopes, an additional option that may be helpful for homebound and hospice patients, have demonstrated a nearly 4-fold increase in the odds of opioid disposal when available.⁸¹ Patients who would prefer to bring their medications to pharmacies for disposal may do so after the pharmacy registers with the US Drug Enforcement Administration (DEA) as a “collector,” allowing them to receive controlled substances for destruction. Current regulations do not require a particular destruction

method, so long as the medication is rendered “nonretrievable” in compliance with applicable federal, state, and local laws.⁸¹

3 | OPIOID STEWARDSHIP

Clinical Scenario 3: Members of a clinic's interdisciplinary Opioid Task Force are discussing a patient receiving chronic opioid therapy who has recently tested positive for tetrahydrocannabinol on a urine drug screen. The patient's PCP starts the conversation, “...although their urine was clean last month, it was dirty this month. She's been stable, but this breaks our contract.” Due to the infraction, the decision is made to discontinue the patient's opioid. The Chair of the Task Force asks clinical pharmacy to put together a taper plan that can be implemented before their next fill, while making sure to “check the prescription drug monitoring program (PDMP) to make sure we're the only ones prescribing.”

3.1 | Opioid stewardship: An evolving practice

The term, “opioid stewardship” is used to describe efforts to prioritize appropriate opioid use while reducing opioid misuse in a variety of




FIGURE 3 Hospital pharmacist activities and involvement in opioid stewardship programs.⁸² Percentages have been rounded to the nearest whole number

health care settings. The prevalence of opioid stewardship programs has been increasing steadily, with over 40% of hospitals reporting an active opioid stewardship program in 2018.⁸² Although these programs have different approaches to stewardship, the most common activities include (in rank order): clinician education and guideline development; routine PDMP inquiries; prioritization of non-pharmacologic and nonopioid pain management strategies; and opioid diversion detection. Pharmacists are becoming increasingly accountable for opioid-related quality measures.⁸³ Figure 3 describes the most common pharmacist activities in opioid stewardship programs. Here we propose a more robust definition, supported by national leaders and accrediting bodies.^{21,49,84,85} Opioid stewardship encompasses an interprofessional, multidisciplinary, and holistic approach to addressing opioid prescribing through monitoring and education, while optimizing multimodal pain management and harm reduction practices, preventing and managing OUD, and using clinical decision support tools and quality metrics to drive decision-making. Pharmacists are a vital part of opioid stewardship efforts and have a tremendous opportunity to place people before policy. As such, we assert that pharmacists should assume a leadership role within the stewardship team.

3.2 | Opioid management: Prescribing, regulations, and harm reduction

Despite the availability of numerous clinical practice guidelines, guidance on individualized opioid prescribing for acute and chronic pain management is highly variable and often based on expert opinion due to the limited evidence available.⁸⁶ Therefore, it is crucial that pharmacists carefully review individual opioid regimens. Specifically, pharmacists should be involved in assessing initial appropriateness of opioid therapy in collaboration with an interprofessional team; designing and implementing opioid prescribing protocols, electronic health record prompts, and order sets to leverage safe prescribing; and monitoring opioid therapy using applicable health information technology and clinical decision support tools. Even small changes, such as setting low quantity defaults on prescription opioid order sets (eg, 10 tablet default), can affect prescribing practices across an entire institution.⁸⁷

Furthermore, in order to benchmark opioid stewardship program success and ensure the service aligns with the Quadruple Aim,⁸⁸ pharmacists should actively participate in the development and monitoring of opioid-related quality and performance measures.⁸³

Evidence is insufficient for the routine use of opioids for chronic noncancer pain (CNCP), though there is good-quality evidence of a dose-dependent risk for serious harm.⁸⁹ When opioids are started early for pain management and at high doses, the likelihood for opioid persistence increases significantly,^{90,91} which in turn increases the risk for numerous negative health outcomes, including: addiction, fractures, sexual dysfunction, and various gastrointestinal, cardiovascular, central nervous, respiratory, and endocrine system disturbances and events.^{89,92} It should be noted that for some patients, the risk vs benefit is acceptable, while for others it is not. Having a pharmacist involved early during treatment is especially important to identify alternative pain management strategies. Nonpharmacologic and non-opioid therapies should be exhausted prior to initiating opioid therapy, with the goal of improving function, reducing pain, and minimizing the harms associated with opioid use. These opioid-sparing therapies should be continued, or sometimes intensified, concurrently with opioid therapy. Lastly, when opioids are warranted for CNCP, clinicians must carefully consider dose, formulation, and duration based on a careful assessment of functionality, pain, and risk mitigation for which standardized assessment tools are available.⁸

In the last few years, numerous stakeholders and policymakers have enacted rules and regulations that limit the duration of opioid prescriptions for acute pain or initial prescriptions, in order to curb opioid-related harms.⁹³ High-dose opioid regimens have also been scrutinized, sometimes leading to involuntary tapers. An opioid taper may be indicated for some, such as when the risks outweigh benefits, clinically meaningful improvements in pain are not achieved, or opioid-induced hyperalgesia is suspected.^{8,17} Furthermore, guidelines exist to help clinicians through important taper considerations, such as how to individualize taper rates and strategies for managing opioid withdrawal.⁹⁴ However, the effect of mandatory opioid tapering policies on patient stability and well-being is concerning.⁹⁵ Only very low-quality evidence supports tapering long-term opioid therapy^{95,96} and the risk for negative health outcomes (fatal overdose and suicide) associated with opioid cessation increases rapidly in patients who have received continuous opioid therapy for long periods of time.¹⁶ Pharmacists can help identify appropriate candidates for tapers, implement taper plans that minimize withdrawal symptoms, and monitor patients for negative health outcomes (eg, suicidal ideation) after a taper has begun. In many circumstances, alternate harm reduction strategies such as co-prescribing naloxone and managing high-risk opioid combinations (eg, benzodiazepines) may be more appropriate to consider. It should be noted that high-risk opioid combinations cannot always be avoided, especially when patients are stabilized or dependent on those concomitant high-risk medications. Nonetheless, pharmacists must support individualized opioid treatment plans, lending their extensive drug knowledge to other clinicians and patients navigating complex drug-drug and drug-disease interactions and instances of misapplied guidance from clinical practice guidelines.

Patient-clinician relationships based on mutual respect and understanding are paramount for effectively managing any chronic disease, pain included. In some instances, it may be necessary to formalize treatment goals and expectations through controlled substance agreements (CSA).

3.3 | Controlled substance agreements

Although frequently utilized in practice, very little high-quality evidence supports the use of CSAs as a means to improve patient care or prevent side effects and diversion.⁹⁷ Guidance on CSAs suggests they should be written to: improve adherence, obtain informed consent, outline prescribing policies, and mitigate the provider's legal risk.⁹⁸ However, in a survey of PCPs, the majority viewed CSAs as a means to reduce professional liability and reduce contact with patients.⁹⁹ This is concerning, as patient safety and wellbeing should be at the center of these agreements. Well-written CSAs should focus on patient safety, while incorporating principles of shared decision-making, ensuring appropriate readability, and be applied consistently. Many example CSAs are available (eg, National Institute on Drug Abuse Sample Patient Agreement Form, available from: <https://www.drugabuse.gov/>), which serve as a starting point that can be adapted to ensure the above criteria are met for each unique patient care setting.

3.4 | "Abuse-deterrent" formulations

Abuse-deterrent opioid formulations (ADF) are also viewed as promising advancements by many health care researchers and policy leaders. An ADF opioid is formulated to deter known or common routes of misuse—primarily crushing for insufflation or dissolving for injection—through a number of different strategies (eg, physical/chemical barriers or opioid agonist/antagonist combinations).¹⁰⁰ Although the recommendations in the FDA's guidance for industry are considered nonbinding, companies are required to conduct post-marketing evaluations of all FDA-approved ADFs with abuse-deterrent labeling claims.

The majority of FDA-approved ADF opioids are relatively new to the market, so there is limited postmarketing data available to judge their impact. The most promising results of ADF opioids appear to occur initially after the introduction of the new formulation. Studies show decreases in the prevalence of opioid misuse with ADFs vs previous formulations of the drug.¹⁰¹ To this end, manufacturers have achieved their stated goal of deterring misuse. However, this does not paint the whole picture. The introduction of crush-resistant formulations, rendering tablets impossible to insufflate, is associated with increasingly dangerous injection practices to circumvent the technology. For example, the ADF technology used in Opana[®] Extended Release (ER) makes the oxycodone poorly soluble and requires more water to fully dissolve, which increases injection burden to 2-4 injections per injection episode.⁶⁴ Subsequently, HIV and HCV

outbreaks and injection-related thrombotic microangiopathy correlate with ADF technology.⁶⁴ In conclusion, ADFs represent a significant cost to the health care system and evidence supporting their use is insufficient.^{23,102-105} In fact, some models predict that ADFs will increase opioid-related mortality over the next decade.²³ Therefore, continued research is needed to clarify the role of ADFs for preventing opioid misuse and pharmacists should stay current with knowledge about the intended and unintended consequences of ADFs.

3.5 | Prescription drug monitoring programs

The PDMP is another increasingly popular tool among policymakers. All 50 states have some form of PDMP, which is used by clinicians to guide decision-making and by law enforcement to track various patterns of opioid use and prescribing. Use of PDMPs is associated with reduced opioid prescribing,¹⁰⁶ reduced rates of high-risk opioid use, and increased screening for SUD.¹⁰⁷ Furthermore, several variables tracked by PDMPs (eg, high opioid doses and multiple pharmacies/providers) correlate with the presence of an OUD diagnosis.¹⁰⁸ Subsequently, there are many ongoing efforts to increase PDMP utilization and efficiency through state mandates and software integration. However, clinicians are still learning about the full impact of this powerful surveillance tool on the current opioid crisis. The effects of PDMPs on fatal and nonfatal overdose rates have been mixed—some studies showing an increase, while others showing a decrease—and the aggregated evidence supporting their use is considered low-strength.¹⁰⁹ Furthermore, the effect of PDMPs on overdose rates seems to vary based on specific program features (eg, nonscheduled drug monitoring) and state regulations. Historically, interventions like PDMPs that reduce prescription opioid access have led to increased use of illegal opioids, as these interventions abruptly drive patients away from prescription opioids. Taking this and other factors into context, this shift toward illegal opioids caused by PDMPs may actually precipitate a net increase in fatal opioid overdoses over the next decade.²³ When PDMP surveillance is warranted, use should be applied uniformly to improve treatment safety and efficacy. When discrepancies arise, they should prompt clarifying conversations between the patient and provider, rather than abrupt opioid cessation and patient abandonment. Pharmacists must also fully consider the ethical dilemma posed by requests for PDMP data from law enforcement pursuing criminal investigations. These requests should always be accompanied by a court order or directed at the PDMPs themselves (vs individual pharmacists).¹¹⁰

3.6 | Universal screening

Although most patients who use opioids will not develop an OUD, a small number will develop a pattern of problematic opioid use. The US Preventive Services Task Force draft guidance recommends universal screening of adults 18 years old and older for SUDs based on evidence of a moderate net benefit, but stipulates that implementation

occur when accurate diagnosis and treatment can be provided in response to a positive screening.¹¹¹ Screening, Brief Intervention and Referral to Treatment (SBIRT) is a useful framework for identifying, reducing, and preventing substance misuse.^{112,113} Theoretically, universal screening for SUD would identify patients in need of help sooner and lead to an appropriate linkage to care. However, attempts to integrate SUD screening into different health care settings has been met with mixed results. Some studies evaluating screening and intervention tools have shown a benefit,¹¹⁴⁻¹¹⁶ which may persist months beyond the brief intervention,¹¹⁴ while other studies have failed to show a significant benefit.^{117,118} Therefore, screening and intervention tools should be developed specific to the needs and resources available to each practice setting. Screening can be completed quickly by pharmacists and other clinical staff and validated tools, such as SBIRT, should be integrated into health records and pharmacy dispensing software for ease of tracking and monitoring.^{119,120} Furthermore, although there is a temptation for pharmacists to use PDMP reports for OUD screening, combining these data with validated screening tools is more beneficial for identifying patients at risk for OUD.^{61,121} Support from administration and department leaders, and sustainable payment models¹²² are needed for increased SUD screening, particularly for integrating these services into community pharmacy settings. Furthermore, when OUD screening tools are utilized, their impact on health outcomes is necessary to ensure consistency and appropriate transitions through care.

4 | OUD TREATMENT

Clinical Scenario 4: Several providers at an outpatient clinic have been asking about “treatment options for opioid addiction.” The director of medical services has responded by asking clinical pharmacy to help develop a new addiction service in collaboration with the family medicine providers and staff. Extended-release intramuscular naltrexone is chosen for the protocol due to its perceived effectiveness and low administrative burden, “...so long as patients detox in the hospital.” Furthermore, it is the only FDA-approved medication a pharmacist can prescribe through a collaborative practice agreement in their state. Six months into the pilot program, the pharmacy team becomes frustrated by the high no-show rate and wishes to add buprenorphine to the protocol. However, only one provider has an X-waiver and the staff are concerned this addition will increase the weekly appointment load and “headaches with insurance and pharmacies.” The pharmacy team is now tasked with exploring buprenorphine prescribing models that integrate pharmacists while minimizing administrative burden.

4.1 | Treatment access and an overreliance on abstinence-based treatment

Treatment for OUD includes psychosocial/behavioral interventions and MOUD (Table 1). Despite decades of data helping clinicians re-categorize OUD as a chronic, relapse-remitting, neurologic disease, the number receiving treatment remains low. The most recent statistics indicate only 34.5% of persons with OUD have received any type of treatment within the past year.¹²³ Furthermore, abstinence-based treatment still dominates the landscape.

Treatment plans that exclusively rely on an opioid taper followed by abstinence are generally considered inferior to MOUD and increase patient harm.^{124,125} However, this very approach remains the most prevalent type of treatment offered for OUD in the United States. As of 2017, among the 13 585 facilities offering treatment for OUD, only 9.5% offered methadone, 29% offered buprenorphine, and 24% offered extended-release naltrexone (XR-NTX).¹²⁶ Of the facilities offering MOUD, rarely did they offer all three MOUDs, further limiting options for patients.^{127,128} OUD treatment should be individualized based on demonstrated treatment efficacy/safety, severity of illness, risk of relapse, patient preference, treatment history, access/availability, cost/coverage, and family/support. However, many federal and state regulations, as well as wholesaler, practice, and payer-specific policies, have led to a lack of access to evidence-based MOUD and an over-reliance on programs offering less effective abstinence-based programs.^{25,129} Even for those seemingly lucky few who obtain MOUD, the benefits may not be fully realized, as these medications are often discontinued prematurely for a variety of reasons.

4.2 | Medication-first treatment approach

Use of opioid agonists (methadone or buprenorphine) to treat OUD is associated with more than a 50% reduced risk for fatal overdose.^{127,130} Therapies this effective are rare, yet MOUD remains underutilized due to lack of treatment access and capacity for patients.^{25,127} Patients face an unacceptable 4- to 7-year lag between OUD onset and initial receipt of treatment in the United States.¹²⁷ The issue, at least in part, is created by stringent US regulations on medication-based treatment. In countries such as France, providers are empowered to prescribe MOUD such as buprenorphine with few excess restrictions, which has led to far higher treatment rates.¹³¹ This highlights a critical need to revise rules and regulations that impede access to MOUD in the United States.

To combat low utilization of MOUD in Missouri, a medication-first treatment approach has been developed.¹³² The tenets of this approach are that patients should receive MOUD quickly; MOUD should be continued as maintenance therapy without arbitrary tapering or discontinuation, unless the patient's condition has worsened; and individualized psychosocial services should be offered, but refusal of these services should not affect medication access. Data 1 year

TABLE 1 Medications for opioid use disorder (MOUD)¹⁹⁵⁻¹⁹⁷

	Opioid agonist		Opioid antagonist
	Methadone (MTD)	Buprenorphine (BUP)	Naltrexone (NTX)
Opioid receptor activity	Full Mu Agonist	Partial Mu and Nociceptin Agonist, Kappa and Delta Antagonist	Mu >> Kappa and Delta Antagonist
Formulations approved for OUD or relapse prevention (generics as indicated)	Oral liquid and tablet (generic)	Sublingual and buccal tablets and film with and without naloxone (generic), long-acting subcutaneous injection, subdermal implant	Oral tablet (generic), long-acting intramuscular injection
Controlled Substance	Yes (C-II)	Yes (C-III)	No
General considerations	Federal regulations limit methadone for an OUD indication to outpatient treatment programs certified by SAMHSA CSAT	Naloxone co-formulated products are generally preferred for OUD	High treatment attrition seen with XR-NTX in clinical trials (relative to opioid agonist therapy)
	Allowable take-home quantity varies, but gradually increases over years of treatment	Providers must receive SAMHSA CSAT Waiver and receive a DEA X-number to prescribe for OUD indication	Oral NTX monotherapy is not recommended for OUD maintenance
	High risk for life-threatening respiratory depression, regardless of use with other CNS depressants	Low risk for life-threatening respiratory depression, unless used with other CNS depressants such as benzodiazepines	
	Variable kinetics		
Considerations when starting therapy	Slow, incremental dose titrations	Slow, incremental dose titrations	7–10 day opioid abstinence required
	EKG monitoring for a QTc baseline and regular monitoring during treatment is recommended	Clear and objective opioid withdrawal must be present ^a	Abstinence often confirmed with urine toxicology report and a naloxone or naltrexone “challenge”
	Conservative initial doses are recommended for those with concomitant CNS depressants, respiratory disorders, or age > 60 years old	Home-induction appropriate for most Collaboration between inpatient and outpatient services is essential	REMS certification required for parenteral formulations
Started in Emergency Department? ^{2b}	Rarely	Yes	Rarely
Pharmacist allowed to prescribe through collaborative practice agreements?	No	Sometimes ^c	Yes
Considerations when stopping or changing therapy	Long half-life prolongs tapers and response to dose adjustments	Long half-life prolongs tapers and response to dose adjustments	Oral NTX is sometimes used between XR-NTX injections or to bridge transitions
	Sub-therapeutic MTD doses (eg, 30-40 mg/day) recommended when converting to BUP		

Abbreviations: BUP, buprenorphine; CNS, central nervous system; DEA, Drug Enforcement Administration; ECG, electrocardiogram; ED, emergency departments; MTD, methadone; NTX, naltrexone; QTc, Q-T interval corrected; REMS, risk evaluation and mitigation strategy; SAMHSA CSAT, Substance Abuse and Mental Health Services Center for Substance Abuse Treatment.

^aPreferably, patients should be experiencing at least moderate withdrawal based on an objective withdrawal scoring tool (eg, clinical opioid withdrawal scale). Buprenorphine can precipitate withdrawal rapidly if started too soon. Micro-dosing buprenorphine induction regimens do exist and are considered exceptions to this rule but have not been evaluated in rigorous clinical trial settings.

^bMethadone may be administered for 72-hours (not prescribed) for opioid withdrawal management in EDs under the “72-hour rule” (21 C.F.R. Sect. 1306.07(b)).¹⁹⁴ Buprenorphine may be administered for 72-hours for opioid withdrawal management in EDs under the “72-hour rule” (21 C.F.R. Sect. 1306.07(b)), but can also be prescribed for addiction by X-waivered providers. Due to the required opioid abstinence period for naltrexone, a patient starting naltrexone in the ED would need to arrive having already been abstinent from opioids for more than 7-10 days or undergo rapid or ultrarapid opioid detoxification under anesthesia.

^cPharmacists in eight states are “mid-level providers” (21 C.F.R. Sect. 1300.01(b28)) and are authorized to prescribe CII-V substances via collaborative practice agreements, but other state/federal regulations may conflict with state-granted privileges.¹⁷²

postimplementation showed significantly improved rates of MOUD-based treatment, reductions in median wait time for MOUD, improved treatment retention, and reduced treatment episode costs when compared with a pre-implementation baseline.¹³² It should be noted that all patients included in this analysis were uninsured and all of the 14 participating treatment agencies received State Targeted Response funds through SAMHSA. However, there are many other models for integrating medication-based therapy into different care settings, several of which include pharmacists.^{133,134} As treatment models evolve, there must be a greater emphasis on continued treatment with MOUD (ie, “maintenance”), vs focusing exclusively on treatment initiation.

Continued use of MOUD is associated with improved patient outcomes and lower health care costs.^{129,135,136} Nearly 20 years ago, it was found that adults with heroin use disorder who received buprenorphine 16 mg/day maintenance therapy had a 75% treatment retention after 12 months (vs 0% for those who received placebo after detox), despite both groups receiving psychosocial therapy.¹³⁷ Urine toxicology screens were also negative for illegal substances in 75% of the samples acquired, and addiction severity index scores were significantly lower compared with baseline for the buprenorphine maintenance arm. Similar results have been reproduced^{130,138} and can be extrapolated to special populations including youth patients with OUD¹³⁹ and patients recently released from incarceration.¹⁴⁰ The effect of continued methadone on health outcomes are comparable with buprenorphine, and both are consistently more efficacious and less costly than abstinence-based therapy.^{129,136-138} By contrast, XR-NTX appears to be less efficacious than sublingual buprenorphine within intention-to-treat comparisons,¹⁴¹ and less cost-effective from health care sector and societal perspectives.¹⁴² Long-acting formulations of buprenorphine have not been compared with XR-NTX, though clinical trials are planned (eg, NCT04219540). In summary, the benefits of continued MOUD outweigh the risks, although side-effects, cost/coverage, and patient choice may interrupt or limit treatment duration and success.

Although evidence clearly supports medication-based treatment, pharmacists' engagement has been limited. Considering the complexity of initiating, adjusting, and maintaining MOUD, the need for pharmacist involvement is compelling. Pharmacists have already played, and continue to play, an integral role in widespread MOUD access in other countries.¹³¹ Involvement of community pharmacists in the United States would have a profound impact on treatment access, given that over 90% of the US population live within 5 minutes of a community pharmacy.¹⁴³ Furthermore, the evidence supports pharmacists as having positive attitudes toward MOUD.^{71,144} With additional training, community pharmacists could be a powerful advocate for persons with OUD and offer an accessible starting point for recovery. Pharmacists unable to commit to the evaluation and management of OUD can still work with patients receiving MOUD to optimize therapy through monitoring and education. It is especially important for that increased oversight to include medication adherence. Recent estimates of MOUD persistence after 1 year was only 21% in a Pennsylvania Medicaid population.¹⁴⁵ It is likely that at least part of the

high MOUD discontinuation rate is associated with modifiable barriers, such as cost/coverage, which pharmacists are well positioned to identify and resolve.

4.3 | Barriers to treatment initiation and sustainable treatment solutions

Treatment initiation occurs in a variety of settings and at different points in a patient's OUD recovery (Table 1). Methadone for OUD is available only through opioid treatment programs certified by the SAMHSA Center for Substance Abuse Treatment in the United States. Unfortunately, opioid treatment programs are not readily accessible for many; nearly 90% of counties have an insufficient number of opioid treatment programs, which has changed minimally over time.¹⁴⁶ However, even with an adequate number of opioid treatment programs, there are still many barriers to successful methadone maintenance, such as supervised daily dosing and maintenance associated with the mandatory services opioid treatment programs are required to provide.¹⁴³ Community pharmacists can provide many of these same services directly to patients.^{71,131} Buprenorphine is also prescribed outside of opioid treatment programs by a growing number of X-waivered providers (eg, “qualifying physician and other practitioners” including: MD, DO, PA, NPs). Providers eligible for a DEA X-waiver has expanded through several landmark Acts (eg, Drug Addiction Treatment Act, Comprehensive Addiction and Recovery Act, and Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act), though recent legislative efforts seek to eliminate the training and registration step entirely (ie, The Mainstreaming Addiction Treatment Act).¹⁴⁷

Buprenorphine prescribing by X-waivered providers through office-based opioid treatment models represents the largest opportunity to expand OUD treatment access using MOUD. The cornerstone of office-based opioid treatment is providers offering buprenorphine through their current clinical practice to increase availability of OUD treatment to patients who need it.¹⁴⁸ However, even with more treatment facilities offering buprenorphine (14% in 2011 to 29% in 2017),¹²⁶ nearly half of the 45 000 approved X-waivered practitioners who are able to prescribe buprenorphine are not actively prescribing.¹⁴⁹ Additionally, existing payment models have not incentivized long-term recovery, as OUD services lack the necessary alignment and integrated economic structures.¹²²

Innovative and sustainable outpatient treatment models, such as the hub and spoke model, have assisted with widespread service implementation in Vermont. In this model, opioid treatment programs serve as “hubs” for patients who require more specialized care and oversight, but once patients are stable, they are referred out to a network of “spokes,” composed of primary care providers offering office-based opioid treatment.^{150,151} Spokes are responsible for monitoring adherence to treatment, coordinating access to recovery support, providing counseling, contingency management, and case management services. This type of collaborative approach to OUD is associated with positive patient perceptions about treatment¹⁵² and can help

generate more X-waivered providers as well as increase training opportunities for all types of health care providers in SUD. Community pharmacies could serve as either hubs or spokes, by referring patients to specialized, intensive, and comprehensive addiction care services after induction, or closely monitoring and adjusting maintenance OUD therapy.^{71,131,153}

Although the majority of OUD treatment occurs in outpatient settings,¹²⁶ initiation of MOUD in the emergency department (ED) and inpatient settings has demonstrated beneficial outcomes including increased patient engagement and 30-day treatment retention and reduced illegal opioid use.¹⁵⁴⁻¹⁵⁷ Patients who have presented to the ED with a nonfatal overdose are at especially high risk for a subsequent fatal overdose,¹²⁵ making OUD treatment all the more necessary. Specialized inpatient consult teams are one viable way to introduce new OUD services to an organization and have demonstrated improvements in OUD treatment access during hospitalization.¹⁵⁶ Also, state Medicaid expansion is associated with lower rates of uninsured hospital encounters for opioid-related events⁸¹ and increased access to OUD and mental health treatment.¹⁵⁸ States that have not expanded Medicaid may see similar improvements with Medicaid expansion due to the scope of services that can be offered during and after opioid-related hospitalizations.

Treatment access and engagement remain challenges when starting therapy. A few of the most substantial barriers include stigma, inadequate reimbursement, lack of institutional support, a lack of expertise, and an inadequate number of X-waivered providers.¹⁵⁹ These barriers must be addressed by medical and regulatory agencies.

4.4 | Changing culture and prescribing barriers

Historically, stigma is the most significant barrier to treatment for OUD. Stigma is often rooted in misperceptions about the underlying pathophysiology of SUDs. Continued use of opioids may be viewed as a moral weakness or willful choice rather than a chronic brain disease heavily influenced by genetic predisposition.^{143,160} The first steps toward implementing new OUD services must address underlying misconceptions about OUD and alleviate concerns held by staff, without being dismissive. Resources are available to help organizations gauge staff readiness, pursue cultural changes, and plan MOUD service implementation.²² With adequate resources and staff buy-in, new services can thrive. Unfortunately, federal regulations stifle that growth by requiring X-waiver training and placing arbitrary caps on treatment capacity. Revising regulations to foster increased treatment access will require unified advocacy. Alongside this issue, we must further understand why some providers do not prescribe to capacity, or even at all once X-waivered, as this can also curtail program efforts.¹⁴⁸

In 2016, the median monthly patient census for over 3000 buprenorphine prescribing physicians was only 13 patients, which is well below capacity.¹⁶¹ Interestingly, a survey of physicians not prescribing to capacity cited a lack of adequate psychosocial support for patients as the most significant barrier to prescribing MOUD.^{148,162}

Although behavioral counseling should be offered to patients with OUD, data supporting increased treatment success with the addition of behavioral support is lacking.^{163,164} Concerns about recurrent opioid use and MOUD diversion are also frequently reported provider concerns.¹⁶⁵ A return of disease symptoms, including return to use, or "relapse," is an inherent part of managing any chronic disease and should not be conflated with treatment failure. In fact, relapse rates are lower for SUDs compared with many other chronic diseases.¹⁶⁶ Diversion concerns are also misplaced, as nonprescribed buprenorphine use overwhelmingly occurs to help patients manage their own (or other's) opioid cravings and withdrawal.^{167,168} In other words, diverted MOUD is most often used for the same reasons as prescribed MOUD, and increased use of diverted buprenorphine is a signal of the limitations within our current treatment system.

Medication cost/coverage is another major barrier to MOUD, which pharmacists can readily address. Buprenorphine/naloxone co-formulated products only recently became generic and XR-NTX remains an expensive brand name medication. Fortunately, recent guidance from SAMHSA has led to the removal of prior authorization requirements for buprenorphine-containing medications on Medicare Part D plans, although coverage of these same medications on state Medicaid plans varies widely.^{10,169} In states that expanded Medicaid, a significant increase in buprenorphine/naloxone prescribing was seen as compared with states that did not expand Medicaid.¹⁷⁰ However, less costly alternatives such as buprenorphine monotherapy may be reasonable to consider for patients with limited resources. State and federal restrictions limit pharmacists' ability to initiate, modify, and sometimes even dispense opioid agonists for OUD.¹⁷¹ Only eight states permit pharmacists to prescribe controlled substances through collaborative practice agreements.¹⁷² Amending state laws in the remaining 42 states is a good starting point for pharmacist advocacy. However, even when progressive state-granted privileges are in place, pharmacists are still unable to become X-waivered due to federal restrictions or are limited to prescribing only certain formulations for MOUD (eg, only oral formulations of buprenorphine can be pharmacist-initiated and modified in California per CA H.S.C. Sect. 11 215).¹⁷³ Unclear regulations also contribute to pharmacist hesitancy. Only recently, the California Board of Pharmacy adopted an official policy stating that pharmacists can in fact initiate and modify MOUD such as buprenorphine.¹⁷⁴ Whether intended or not, current state and federal regulations affecting pharmacist-led OUD management favor XR-NTX prescribing over other more effective forms of MOUD like buprenorphine. Therefore, pharmacists must advocate for regulatory changes that enable initiation and modification of all effective forms of MOUD. Removing restrictions on methadone by eliminating the opioid treatment program requirement or allowing opioid treatment programs to adapt to our current needs (eg, mobile opioid treatment programs)¹⁷⁵ are other logical next steps to improving treatment access. However, allowing methadone to be dispensed for OUD in community pharmacies, a practice that has been ongoing in other countries for decades,⁷¹ may be the most impactful next step.¹⁷⁶ While limitations are addressed, pharmacists can still play a key role in supporting recovery from OUD by working collaboratively

with patients, payers, and clinicians to identify and minimize side-effects, improve adherence, and quickly resolve prescribing and dispensing delays, which risk significant consequences.

5 | STIGMA, ADVOCACY, AND TRAINING

Clinical Scenario 5: A community pharmacist wants to become more involved in harm reduction practices, as their city has been hit hard by opioid-related overdose fatalities. The pharmacy's policy on syringe sale has changed over the years and currently the pharmacist can only sell syringes to patients with a prescription for insulin. The store manager is also concerned about employee safety if syringe sales are increased. Furthermore, although the whole pharmacy received training on overdose reversal using naloxone, there's still confusion about the new state law allowing pharmacists to dispense under a standing order. The pharmacist in charge has said that, "until we know the insurance companies aren't going to claw their money back, we have to run it cash only." Discouraged by leadership's response, the pharmacist hopes to first reshape the pharmacy's culture around SUDs and harm reduction.

5.1 | Stigma: A barrier to care

While there are many definitions that exist, one of the earliest definitions of stigma is the perception of someone as less desirable, reducing that individual from "a whole and usual person to a tainted, discounted one."¹⁷⁷ Contemporary definitions further classify stigma as perceived stigma, self-stigma, enacted stigma, and structural stigma—all of which originate from a variety of individual and external factors that may be systematic and unintentional.¹⁷⁸ Put differently, stigma, as it relates to OUD, is complex, multifaceted, and pervasive.

Stigma remains one of the most common impediments to starting and continuing MOUD. The misconception of SUDs as a moral weakness or willful choice rather than a chronic disease has created disparities in public perceptions about SUD vs other chronic conditions such as mental illness.^{160,179,180} Specifically, respondents were more likely to prefer social distance, permit discrimination, deny employment, and deny housing for persons with SUD over those with mental illness. Consequently, individuals with OUD are met with challenges such as a limited number of treatment centers, denied employment/housing, and barriers to MOUD by health insurers or during incarceration.^{160,181} Even among persons in recovery, the use of MOUD is often perceived as a lack of willpower or "crutch" rather than a step toward recovery.¹⁶⁰ In fact, certain Narcotics Anonymous meetings

limit participation for members utilizing MOUD, only referring to those who are entirely abstinent to any opioid (including MOUD) as "clean."¹⁸² Although recovery is a common goal, the use of stigmatizing language and practices discourages use of MOUD, and reinforces the misconception that abstinence-based therapy is preferred.

5.2 | Language impacts patient outcomes

Stigmatizing language is a threat to optimizing the care of patients with SUDs. Unfortunately, a recent analysis of public media indicates the use of stigmatizing language may be increasing.¹⁸³ Traditional terminology associated with SUDs focused on the potential moral failings of a person in place of the science of this chronic brain disease.¹⁸⁴ Words such as "addict," "drug habit," "abuser," "dirty/clean drug screen" promote the notion that those with OUD can simply stop "abusing" substances, and are thereby "dirty" when continuing to do so, which does not align with our neurobiological understanding of OUD. The stigma promoted through negative language builds barriers to care. Nearly 15% of adult patients in 2018 who identified as needing, but not receiving SUD treatment, did not seek out treatment due to concerns that treatment would lead to their neighbors and community forming negative opinions about them.⁷³ Additionally, language associated with SUDs has a significant impact on implicit and explicit bias of health care clinicians. Terms like "addict" and "substance abuser," among others, elicit negative bias in health professionals¹⁸⁵ and diminish treatment outcomes.¹⁸⁶ Public awareness and educational campaigns along with professional development strategies seek to combat this stigma.¹⁸⁷ See Table 2 for examples of stigmatizing and preferred terms.

5.3 | Pharmacist advocacy and training

As part of the Oath of a Pharmacist, we vow to "embrace and advocate [for] changes that improve patient care."¹⁸⁸ The opportunities to advocate for opioid harm reduction practices and access to treatment

TABLE 2 Stigmatizing and supportive terminology related to substance use disorder^{185,186}

Stigmatizing terms to avoid	Supportive terminology to utilize
Substance abuse, substance dependence, drug habit	Substance misuse, substance use disorder
Addict, drug abuser, junkie	Person who uses drugs, person with a substance use disorder
Clean	Remission, recovery
Clean/dirty toxicology screen	Negative/positive toxicology screen
Relapse	Return of symptoms, continued use
Opioid replacement/substitution	Medication, pharmacotherapy, medication-based treatment
High-risk group	High-risk behavior
Opioid overdose	Breathing emergency

for patients with SUD are abundant at local, state, and federal levels. Expanding naloxone access through NALs is one example where advocacy may result in substantive improvements in patient outcomes.⁴⁷ However, there must also be sufficient pharmacist buy-in, training, and resources, otherwise progress will stagnate despite progressive state privileges.⁴⁸ Providing education on harm reduction, opioid stewardship, and OUD early in student training,¹⁸⁹ and supplemental knowledge throughout a pharmacists' career, is essential for building individual knowledge and confidence in these areas.

Doctor of Pharmacy programs have reacted to the opioid crisis in different ways. Some have developed specialized activities centered on overdose response training, but there is no single approach. Collectively, programs are offering nearly 500 different opioid-related activities, categorized as being either education- (65%), service- (23%), research- (22%), practice- (8%), or advocacy-based (4%) activities.¹⁹⁰ However, curricular revisions often take a considerable amount of time and convincing to create change. Postgraduate training programs (eg, residency and fellowship) can react more expediently. Program preceptors and directors should strive to offer direct patient care opportunities in pain and SUD treatment within general postgraduate year one (PGY1) residencies, given the increasing prevalence of hospitalizations for opioid-related complications, as well as ambulatory care postgraduate year two (PGY2) residencies, recognizing the crucial role of primary care clinicians in addressing these issues. Furthermore, available PGY2 specialty programs in pain and palliative care and psychiatric pharmacy must be expanded. Per the American Society of Health-System Pharmacists Online Residency Directory (2019/2020), there are only 25 accredited pain and palliative care PGY2 programs and 73 accredited psychiatric PGY2 programs nationally.¹⁹² Expanding opportunities for PGY2 training will not only increase pharmacist specialization in the areas of OUD and pain management, but will also provide momentum toward recognizing pain and palliative care, or perhaps addiction medicine, as a pharmacy specialty by the Board of Pharmacy Specialties. Board certification is the gold standard for pharmacists and an excellent way for pharmacists to increase scope of practice and state privileges.¹⁹¹ Lastly, as with previous areas of practice innovation, payment for cognitive services is required to provoke the systemic change necessary to support pharmacist implementation of effective OUD-related interventions. Changes in Medicare eligibility and coverage through the SUPPORT act (eg, opioid treatment program eligibility for Medicare enrollment and bundled payments for OUD services, including telehealth-based services)¹⁹³ are notable improvements, but investment in primary care SUD services is still lacking. The reality is that office-based opioid treatments providing comprehensive medication-based care require additional personnel (eg, case managers, behavioral health consultants, and peer specialists), have increased time spent on visits and care coordination, and new regulatory considerations that serve to disincentivize practices from offering evidence-based care. Therefore, innovative payment models are necessary to support evidence-based and comprehensive care.¹²²

6 | CONCLUSION

Current evidence supports a multifaceted and collaborative approach to the opioid crisis. Pharmacists can augment ongoing opioid stewardship, harm reduction, and OUD treatment efforts across the spectrum of care. Efforts to heal damages caused by prescription opioids are warranted but addressing only this aspect of the crisis is shortsighted. There must also be efforts to reduce the harms associated with continued opioid use, both medical and nonmedical, as well as evidence-based and accessible treatment for OUD. In fact, the very language we use to describe our patients and their illnesses can impact quality of life and treatment outcomes. Policies that limit clinicians' ability to practice to the extent of their education and training, impede patient access to care, or potentiate the harms associated with opioid use must be revised to reflect current evidence and needs. Lastly, sustainable funding for training, research, and clinical services must be available to identify and provide the safest and most effective pain and SUD treatment modalities, strategies to reduce harm associated with opioid use, and solutions to ongoing barriers to treatment.

Clinical Scenario Considerations:

For all of the clinical scenarios, a multifaceted, patient-centered solution is required; no single therapeutic approach or policy is sufficient. Furthermore, a collaborative interprofessional approach is ideal to maximize patient benefit. While the ideal response to each scenario may vary in practice, the following suggestions are offered by the authors:

Scenario 1. In this scenario, a pharmacist is consulted to assist a provider in managing a patient's chronic pain. Although notably interprofessional, the request demonstrates a non-patient-centered approach to pain management, likely driven by fear and stigma. It is clear that there are system pressures to de-prescribe opioids. Pharmacists must advocate for patients in these situations, ensuring effective therapies are continued when benefits outweigh harms, and that both the patient and provider have agreed upon realistic and attainable pain goals. There are positives to highlight as well. Specifically, the request for naloxone education demonstrates the adoption of harm reduction principles shown to reduce the incidence of fatal overdose. The pharmacist should involve the patient's friends and family in the conversation about naloxone, as they may be responsible for administering naloxone during an emergency.

Scenario 2. Pharmacists educate patients on naloxone every day, but our approach to these challenging conversations is important. In this scenario, the pharmacist senses the patient's defensiveness and immediately employs a motivational interviewing technique that acknowledges and alleviates the patient's concerns. The focus of this

conversation is shifted away from the patient and is placed on the inherent risks of continued opioid therapy. Instead of giving up on the interaction, the pharmacist emphasizes medication safety by prioritizing a harm reduction intervention proven to reduce emergency department visits and overdose mortality rates to a greater extent than opioid dose reduction.

Scenario 3. In this scenario, the members are discussing how to proceed after a controlled substance agreement (CSA) infraction. Similar to Scenario 1, we see a non-patient-centered approach to pain management. In addition to use of stigmatizing language (eg, "dirty" vs "positive"), the committee has failed to fully understand the patient's reason for cannabis use and has hastily pursued a life-changing decision to taper the patient's opioid therapy. The pharmacist in this case should recognize harms associated with abrupt opioid tapers, advocate for more information regarding the patient's use of cannabis, pain etiology, and response to opioid therapy, and ensure the patient understands their CSA. The patient's responses could aid the team in identifying additional care needs or lead to the conclusion that concurrent cannabis use is acceptable.

Scenario 4. This scenario depicts struggles encountered by a new pharmacist-led opioid use disorder (OUD) service within a family medicine practice. Unfortunately, there are considerable barriers to prescribing opioid-agonist therapies (eg, buprenorphine) in primary care, especially for pharmacists working under collaborative practice agreements, which reduce medications for opioid use disorder (MOUD) options for patients. Pharmacists must resist the temptation to manage OUD with opioid antagonists exclusively and instead advocate for state and federal regulations and reimbursement models that support all forms of MOUD in primary care. In the meantime, the clinic could partner with opioid treatment programs (ie, hub-and-spoke model) or other health care agencies to facilitate, sustain, and expand access to opioid agonist therapy.

Scenario 5. The final scenario describes a pharmacist in the community advancing harm reduction practices at their pharmacy. However, the pharmacist is met with barriers including restrictive syringe and naloxone policies and misconceptions and prejudice toward people who use drugs. Fortunately, store policies can be revised and unclear rules and regulations can be clarified. Changing culture is often more challenging and time-consuming. It will be important for the pharmacist to address staff concerns, as well as educate and consider initial compromise. After gaining momentum, it will then be important to galvanize members around specific outreach and advocacy initiatives, disseminate successes and failures, and connect with other harm reduction agencies in the community.

ACKNOWLEDGEMENTS

The committee recognizes Dr Chris Herndon, Pharm.D., CPE, FASHP, and Dr Jayne Pawasauskas, Pharm.D., BCPS, for their input as content experts. Additionally, the committee recognizes Dr Seth Gomez, Pharm.D., BCPP, for additional guidance and the University of South Florida IMpact team for graphic design support.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

ORCID

Scott A. Coon  <https://orcid.org/0000-0002-1534-6114>

Lucas G. Hill  <https://orcid.org/0000-0001-5958-0159>

Robert W. Hutchison  <https://orcid.org/0000-0002-0013-328X>

Lindsay M. Arnold  <https://orcid.org/0000-0001-8199-2125>

Jennie B. Jarrett  <https://orcid.org/0000-0003-0583-308X>

Anne R. Ottney  <https://orcid.org/0000-0002-0967-4453>

Alvin B. Oung  <https://orcid.org/0000-0001-5569-8248>

Nathan A. Painter  <https://orcid.org/0000-0003-4838-6400>

Michael A. Smith  <https://orcid.org/0000-0002-9762-0104>

Paul M. Stranges  <https://orcid.org/0000-0003-3797-2762>

Tran H. Tran  <https://orcid.org/0000-0002-0537-7566>

Amanda R. McFee Winans  <https://orcid.org/0000-0003-3835-7227>

Jeffrey P. Bratberg  <https://orcid.org/0000-0002-2240-5768>

REFERENCES

- Comerci G, Katzman J, Duhigg D. Controlling the swing of the opioid pendulum. *N Engl J Med*. 2018;378(8):691–693.
- Baker DW. History of the Joint Commission's pain standards: Lessons for today's prescription opioid epidemic. *JAMA*. 2017;317(11):1117–1118.
- Okie S. A flood of opioids, a rising tide of deaths. *N Engl J Med*. 2010;363(21):1981–1985.
- Schuchat A, Houry D, Guy GP. New data on opioid use and prescribing in the United States. *JAMA*. 2017;318(5):425–426.
- Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths—United States, 2013–2017. *MMWR Morb Mortal Wkly Rep*. 2018;67(5152):1419–1427.
- Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: A public health approach to an epidemic of addiction. *Annu Rev Public Health*. 2015;36:559–574.
- Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000–2014. *MMWR Morb Mortal Wkly Rep*. 2016;64(50–51):1378–1382.
- Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. *MMWR Recomm Rep*. 2016;65(1):1–49.
- Centers for Disease Control and Prevention. *Quality improvement and care coordination: Implementing the CDC guideline for prescribing opioids for chronic pain*. Atlanta, GA: National Center for Injury Prevention and Control, Division of Unintentional Injury Prevention, 2018 [cited 2019 Nov]. Available from: <https://www.cdc.gov/drugoverdose/pdf/prescribing/CDC-DUIP-QualityImprovementAndCareCoordination-508.pdf>.
- Meara E, Horwitz JR, Powell W, et al. State legal restrictions and prescription-opioid use among disabled adults. *N Engl J Med*. 2016;375(1):44–53.
- Babu KM, Brent J, Juurlink DN. Prevention of opioid overdose. *N Engl J Med*. 2019;380(23):2246–2255.

12. Wheeler E, Jones TS, Gilbert MK, Davidson PJ, Centers for Disease Control and Prevention (CDC). Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. *MMWR Morb Mortal Wkly Rep.* 2015;64(23):631–635.
13. Murphy SM, Morgan JR, Jeng PJ, Schackman BR. Will converting naloxone to over-the-counter status increase pharmacy sales? *Health Serv Res.* 2019;54(4):764–772.
14. Bohnert ASB, Ilgen MA. Understanding links among opioid use, overdose, and suicide. *N Engl J Med.* 2019;380(1):71–79.
15. Kroenke K, Alford DP, Argoff C, et al. Challenges with implementing the Centers for Disease Control and Prevention opioid guideline: A consensus panel report. *Pain Med.* 2019;20(4):724–735.
16. Oliva EM, Bowe T, Manhapra A, et al. Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. *BMJ.* 2020;368:m283. <https://www.bmj.com/content/bmj/368/bmj.m283.full.pdf>
17. Dowell D, Haegerich T, Chou R. No shortcuts to safer opioid prescribing. *N Engl J Med.* 2019;380(24):2285–2287.
18. Wilson N, Kariisa M, Seth P, Smith H, Davis NL. Drug and opioid-involved overdose deaths—United States, 2017–2018. *MMWR Morb Mortal Wkly Rep.* 2020;69(11):290–297.
19. Hempstead K, Phillips J. Divergence in recent trends in deaths from intentional and unintentional poisoning. *Health Aff.* 2019;38(1):29–35.
20. Coffin PO, Behar E, Rowe C, et al. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. *Ann Intern Med.* 2016;165(4):245–252.
21. Sandbrink F, Uppal R. The time for opioid stewardship is now. *Jt Comm J Qual Patient Saf.* 2019;45(1):1–2.
22. Coffin P, Banta-Green C. The dueling obligations of opioid stewardship. *Ann Intern Med.* 2014;161(4):307–308.
23. Pitt AL, Humphreys K, Brandeau ML. Modeling health benefits and harms of public policy responses to the US opioid epidemic. *Am J Public Health.* 2018;108(10):1394–1400.
24. Harm Reduction Coalition. Principles of harm reduction. Available from: <http://harmreduction.org/about-us/principles-of-harm-reduction/>
25. Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. *Am J Public Health.* 2015;105(8):e55–e63.
26. Bratberg JP, Smothers ZPW, Collins K, Erstad B, Ruiz Veve J, Muzyk AJ. Pharmacists and the opioid crisis: A narrative review of pharmacists' practice roles. *J Am Coll Clin Pharm.* 2020;3(2):478–484.
27. Adapt Pharma, Inc. NARCAN® (naloxone hydrochloride) nasal spray. Radnor, PA: Adapt Pharma, Inc., 2015.
28. IBM Micromedex®. Naloxone. DRUGDEX®. Greenwood Village, CO: Truven Health Analytics, 2018 [cited 2019 Aug]. Available from: <http://www.micromedexsolutions.com/>.
29. Edwards ET, Edwards ES, Davis E, Mulcare M, Wiklund M, Kelley G. Comparative usability study of a novel auto-injector and an intranasal system for naloxone delivery. *Pain Ther.* 2015;4(1):89–105.
30. Eggleston W, Podolak C, Sullivan RW, Pacelli L, Keenan M, Wojcik S. A randomized usability assessment of simulated naloxone administration by community members. *Addiction.* 2018;113(12):2300–2304.
31. Eggleston W, Calleo V, Kim M, Wojcik S. Naloxone administration by untrained community members. *Pharmacotherapy.* 2020;40(1):84–88.
32. Tippey KG, Yovanoff M, LS MG, Sneeringer P. Comparative human factors evaluation of two nasal naloxone administration devices: NARCAN® nasal spray and naloxone prefilled syringe with nasal atomizer. *Pain Ther.* 2019;8(1):89–98. <https://doi.org/10.1007/s40122-019-0118-0>.
33. Gertner AK, Domino ME, Davis CS. Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid. *Drug Alcohol Depend.* 2018;190:37–41.
34. Han JK, Hill LG, Koenig ME, Das N. Naloxone counseling for harm reduction and patient engagement. *Fam Med.* 2017;49(9):730–733.
35. Katzman JG, Takeda MY, Greenberg N, et al. Association of take-home naloxone and opioid overdose reversals performed by patients in an opioid treatment program. *JAMA Netw Open.* 2020;3(2):e200117.
36. American Foundation for AIDS Research. 2017. Syringe service programs and the opioid epidemic. Available from: www.amfar.org/ssp-opioid-epidemic/
37. Behar E, Rowe C, Santos G-M, Murphy S, Coffin PO. Primary care patient experience with naloxone prescription. *Ann Fam Med.* 2016;14(5):431–436.
38. Behar E, Bagnulo R, Coffin PO. Acceptability and feasibility of naloxone prescribing in primary care settings: A systematic review. *Prev Med.* 2018;114:79–87.
39. Follman S, Arora VM, Lyttle C, Moore PQ, Pho MT. Naloxone prescriptions among commercially insured individuals at high risk of opioid overdose. *JAMA Netw Open.* 2019;2(5):e193209.
40. Jones CM, Compton W, Vythilingam M, Giroir B. Naloxone coprescribing to patients receiving prescription opioids in the Medicare part D program, United States, 2016–2017. *JAMA.* 2019;322(5):462–464.
41. Sohn M, Talbert JC, Huang Z, Lofwall MR, Freeman PR. Association of naloxone coprescription laws with naloxone prescription dispensing in the United States. *JAMA Netw Open.* 2019;2(6):e196215.
42. Green TC, Davis C, Xuan Z, Walley AY, Bratberg J. Laws mandating coprescription of naloxone and their impact on naloxone prescription in five US states, 2014–2018. *Am J Public Health.* 2020;110(6):881–887.
43. U.S. Food and Drug Administration. FDA Requiring Labeling Changes for Opioid Pain Medicines, Opioid Use Disorder Medicines Regarding Naloxone. 2020 [cited 2020 July]. Available from: <https://www.fda.gov/news-events/press-announcements/fda-requiring-labeling-changes-opioid-pain-medicines-opioid-use-disorder-medicines-regarding>.
44. McClellan C, Lambdin BH, Ali MM, et al. Opioid-overdose laws association with opioid use and overdose mortality. *Addict Behav.* 2018;86:90–95.
45. Freeman PR, Hankosky ER, Lofwall MR, Talbert JC. The changing landscape of naloxone availability in the United States, 2011–2017. *Drug Alcohol Depend.* 2018;191:361–364.
46. Xu J, Davis CS, Cruz M, Lurie P. State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. *Drug Alcohol Depend.* 2018;189:37–41.
47. Abouk R, Pacula RL, Powell D. Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose. *JAMA Intern Med.* 2019;179(6):805–811.
48. Puzantian T, Gasper JJ. Provision of naloxone without a prescription by California pharmacists 2 years after legislation implementation. *JAMA.* 2018;320(18):1933–1934.
49. Evoy KE, Hill LG, Groff L, Mazin L, Carlson CC, Reveles KR. Naloxone accessibility without a prescriber encounter under standing orders at community pharmacy chains in Texas. *JAMA.* 2018;320(18):1934–1937.
50. Hill LG, Reveles KR, Evoy KE. State-level approaches to expanding pharmacists' authority to dispense naloxone may affect accessibility. *JAMA Intern Med.* 2019;179(10):1442–1443.
51. Palombi L, Hawthorne AN, Lunos S, Melgaard K, Dahly A, Blue H. Community pharmacist utilization of legislation that allows impact on the opioid crisis in the state of Minnesota: A mixed-methods approach. *J Pharm Pract.* 2019;14:897190019841747.

52. Lai Joyce Chun K, Olsen A, Taing M-W, et al. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities. *Res Social Adm Pharm.* 2019;15(8):1014–1020.
53. Evoy KE, Groff L, Hill LG, Godinez W, Gandhi R, Reveles KR. Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas. *J Am Pharm Assoc.* 2020;60(1):81–86.
54. Abd-Elseyed A, Albert CA, Fischer M, Anderson B. Naloxone academic detailing: Role of community outreach teaching. *Curr Pain Headache Rep.* 2018;22(11):72.
55. Devries J, Rafie S, Polston G. Implementing an overdose education and naloxone distribution program in a health system. *J Am Pharm Assoc.* 2017;57(2S):S154–S160.
56. Bounthavong M, Harvey MA, Wells DL, et al. Trends in naloxone prescriptions prescribed after implementation of a national academic detailing service in the veterans health administration: A preliminary analysis. *J Am Pharm Assoc.* 2017;57(2S):S68–S72.
57. Strand MA, Eukel H, Frenzel O, Skoy E, Steig J, Werremeyer A. Program evaluation of the opioid and naloxone education (ONE Rx) program using the RE-AIM model. *Res Social Adm Pharm.* 2020;16(9):1248–1254.
58. Gunn AH, Smothers ZPW, Schramm-Sapyta N, Freiermuth CE, MacEachern M, Muzyk AJ. The emergency department as an opportunity for naloxone distribution. *West J Emerg Med.* 2018;19(6):1036–1042.
59. Sexton SM, Armstrong A, Gattton O, Rhodes LA, Marciniak MW. A standardized team-based approach for identifying naloxone-eligible patients in a grocery store pharmacy. *J Am Pharm Assoc.* 2019;59(4S):S95–S100.
60. Griffin S, Wishart B, Bricker K, Luebchow A. Impact of a pharmacist-driven intervention on the outpatient dispensing of naloxone. *J Am Pharm Assoc.* 2019;59(4S):S161–S166.
61. Ronan MV, Herzig SJ. Hospitalizations related to opioid abuse/dependence and associated serious infections increased sharply, 2002–12. *Health Aff.* 2016;35:832–837.
62. Stopka TJ, Donahue A, Hutcheson M, Green TC. Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015. *J Am Pharm Assoc.* 2017;57(2S):S34–S44.
63. Teshale EH, Asher A, Aslam MV, et al. Estimated cost of comprehensive syringe service program in the United States. *PLoS One.* 2019;14(4):e0216205.
64. Broz D, Zibbell J, Foote C, et al. Multiple injections per injection episode: High-risk injection practice among people who injected pills during the 2015 HIV outbreak in Indiana. *Int J Drug Policy.* 2018;52:97–101.
65. Centers for Disease Control and Prevention. Managing HIV and hepatitis c outbreaks among people who inject drugs: A guide for state and local health departments. 2019 [cited 2019 Sept]. Available from: <https://www.cdc.gov/hiv/pdf/programresources/guidance/cluster-outbreak/cdc-hiv-hcv-pwid-guide.pdf>
66. Abdul-Quader AS, Feelemyer J, Modi S, et al. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: A systematic review. *AIDS Behav.* 2013;17(9):2878–2892.
67. Levine H, Bartholomew TS, Rea-Wilson V, et al. Syringe disposal among people who inject drugs before and after the implementation of a syringe services program. *Drug Alcohol Depend.* 2019;202:13–17.
68. Adams JM. Making the case for syringe services programs. *Public Health Rep.* 2020;135(1_suppl):10S–12S.
69. Sherman SG, Schneider KE, Park JN, et al. PrEP awareness, eligibility, and interest among people who inject drugs in Baltimore, Maryland. *Drug Alcohol Depend.* 2019;195:148–155.
70. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United State—2017 update clinical practice guideline. 2017 [cited 2020 March]. Available from: <https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf>
71. Matheson C, Bond CM, Tinelli M. Community pharmacy harm reduction services for drug misusers: national service delivery and professional attitude development over a decade in Scotland. *J Public Health.* 2007;29(4):350–357.
72. Kennedy-Hendricks A, Gielen A, McDonald E, McGinty EE, Shields W, Barry CL. Medication sharing, storage, and disposal practices for opioid medications among US adults. *JAMA Intern Med.* 2016;176(7):1027–1029.
73. Substance Abuse and Mental Health Services Administration. *Key substance use and mental health indicators in the United States: Results from the 2018 national survey on drug use and health (HHS publication no. PEP19-5068, NSDUH Series H-54)*. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, 2019 [cited 2020 Mar]. Available from: <https://www.samhsa.gov/data/>.
74. Jones CM, Paulozzi LJ, Mack KA. Sources of prescription opioid pain relievers by frequency of past-year nonmedical use United States, 2008–2011. *JAMA Intern Med.* 2014;174(5):802–803.
75. Maughan BC, Hersh EV, Shofer FS, et al. Unused opioid analgesics and drug disposal following outpatient dental surgery: A randomized controlled trial. *Drug Alcohol Depend.* 2016;168:328–334.
76. Varisco TJ, Fleming ML, Bapat SS, Wanat MA, Thornton D. Health care practitioner counseling encourages disposal of unused opioid medications. *J Am Pharm Assoc.* 2019;59(6):809–815.e5.
77. Hasak JM, Roth Bettlach CL, Santosa KB, Larson EL, Stroud J, Mackinnon SE. Empowering post-surgical patients to improve opioid disposal: A before and after quality improvement study. *J Am Coll Surg.* 2018;226(3):235–240.e3.
78. Gray J, Hagemeyer N, Brooks B, Alamian A. Prescription disposal practices: A 2-year ecological study of drug drop box donations in appalachia. *Am J Public Health.* 2015;105(9):e89–e94.
79. Conn J. Summit County group distributes 60,000 disposal pouches for prescription drugs. 2018 [cited 2019 Aug]. Available from: https://www.cleveland.com/akron/2018/08/summit_county_community_partne.html
80. Title 40 Code of Federal Regulations. Section 266.505. 2019. Available from: <https://www.federalregister.gov/d/2019-01298/page-5819>
81. Drug Enforcement Administration. Disposal of controlled substances; Final Rule, 21 C.F.R. Parts 1300, 1301, 1304, et al. 2014.
82. Pedersen CA, Schneider PJ, Ganio MC, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: Monitoring and patient education-2018. *Am J Health-Syst Pharm.* 2019;76(14):1038–1058.
83. Andrawis M, Ellison LTCC, Riddle S, et al. Recommended quality measures for health-system pharmacy: 2019 update from the Pharmacy Accountability Measures Work Group. *Am J Health-Syst Pharm.* 2019;76(12):874–887.
84. Tolba R, Meselhy E, Guerra CE. The opioid epidemic and pain medicine specialists: Where to begin and what is next? *Ochsner J.* 2018;18(1):20–22.
85. Weiner SG, Price CN, Atalay AJ, et al. A health system-wide initiative to decrease opioid-related morbidity and mortality. *Jt Comm J Qual Patient Saf.* 2019;45(1):3–13.
86. Committee on Evidence-Based Clinical Practice Guidelines for Prescribing Opioids for Acute Pain, Board on Health Care Services, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. *Framing opioid prescribing guidelines for acute pain: Developing the evidence*. Washington, DC: National

- Academies Press, 2019 [cited 2019 Dec 20]. Available from: <https://www.nap.edu/catalog/25555>.
87. Delgado MK, Shofer FS, Patel MS, et al. Association between electronic medical record implementation of default opioid prescription quantities and prescribing behavior in two emergency departments. *J Gen Intern Med*. 2018;33(4):409–411.
 88. Bodenheimer T, Sinsky C. From triple to quadruple aim: care of the patient requires care of the provider. *Ann Fam Med*. 2014;12(6):573–576.
 89. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a national institutes of health pathways to prevention workshop. *Ann Intern Med*. 2015;162(4):276–286.
 90. Alam A, Gomes T, Zheng H, Mamdani MM, Juurlink DN, Bell CM. Long-term analgesic use after low-risk surgery: A retrospective cohort study. *Arch Intern Med*. 2012;172(5):425–430.
 91. Webster BS, Verma SK, Gatchel RJ. Relationship between early opioid prescribing for acute occupational low back pain and disability duration, medical costs, subsequent surgery and late opioid use. *Spine*. 2007;32(19):2127–2132.
 92. Baldini A, Von Korff M, Lin EHB. A review of potential adverse effects of long-term opioid therapy: A practitioner's guide. *Prim Care Companion CNS Disord*. 2012;14(3):PCC.11m01326.
 93. Chua K-P, Brummett CM, Waljee JF. Opioid prescribing limits for acute pain: Potential problems with design and implementation. *JAMA*. 2019;321(7):643–644.
 94. The U.S. Department of Health and Human Services Working Group on Patient-Centered Reduction or Discontinuation of Long-term Opioid Analgesics. HHS guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics. 2019 [cited 2020 Mar]. Available from: https://www.hhs.gov/opioids/sites/default/files/2019-10/Dosage_Reduction_Discontinuation.pdf
 95. Darnall BD, Juurlink D, Kerns RD, et al. International stakeholder community of pain experts and leaders call for an urgent action on forced opioid tapering. *Pain Med*. 2019;20(3):429–433.
 96. Frank JW, Lovejoy TI, Becker WC, et al. Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: A systematic review. *Ann Intern Med*. 2017;167(3):181–191.
 97. Starrels JL, Becker WC, Alford DP, Kapoor A, Williams AR, Turner BJ. Systematic review: Treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. *Ann Intern Med*. 2010;152(11):712–720.
 98. Tobin DG, Keough Forte K, Johnson MGS. Breaking the pain contract: A better controlled-substance agreement for patients on chronic opioid therapy. *Cleve Clin J Med*. 2016;83(11):827–835.
 99. Starrels JL, Wu B, Peyser D, et al. It made my life a little easier: primary care providers' beliefs and attitudes about using opioid treatment agreements. *J Opioid Manag*. 2014;10(2):95–102.
 100. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Abuse-deterrent opioids—Evaluation and labeling guidance for industry. 2015 [cited 2019 Oct]. Available from: <https://www.fda.gov/files/drugs/published/Abuse-Deterrent-Opioids-Evaluation-and-Labeling.pdf>
 101. Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: Initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. *J Pain*. 2013;14(4):351–358.
 102. Becker WC, Fiellin DA. Abuse-deterrent opioid formulations—Putting the potential benefits into perspective. *N Engl J Med*. 2017;376(22):2103–2105.
 103. Kumar VM, Agboola F, Synnott PG, et al. Impact of abuse deterrent formulations of opioids in patients with chronic pain in the United States: A cost-effectiveness model. *Value Health*. 2019;22(4):416–422.
 104. Litman RS, Pagán OH, Cicero TJ. Abuse-deterrent opioid formulations. *Anesthesiology*. 2018;128(5):1015–1026.
 105. Institute for Clinical and Economic Review. Abuse-deterrent formulations of opioids: Effectiveness and value. 2017 [cited 2020 Mar]. Available from: https://icer-review.org/wp-content/uploads/2016/08/NECEPAC_ADF_Final_Report_08_08_17.pdf
 106. Bao Y, Pan Y, Taylor A, et al. Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. *Health Aff*. 2016;35(6):1045–1051.
 107. Reifler LM, Droz D, Bailey JE, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? *Pain Med*. 2012;13(3):434–442.
 108. Cochran G, Lo-Ciganic W-H, Gellad WF, et al. Prescription opioid quality measures applied among Pennsylvania Medicaid enrollees. *J Manag Care Spec Pharm*. 2018;24(9):875–885.
 109. Fink DS, Schleimer JP, Sarvet A, et al. Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: A systematic review. *Ann Intern Med*. 2018;168(11):783–790. <https://doi.org/10.7326/M17-3074>.
 110. Brushwood, DB. Unauthorized police access to PDMP data. *Pharmacy Today*. 2013 [cited 2019 Dec]. Available from: [https://www.pharmacytoday.org/article/S1042-0991\(15\)31271-8/fulltext](https://www.pharmacytoday.org/article/S1042-0991(15)31271-8/fulltext)
 111. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for unhealthy drug use: US preventive services task force recommendation statement. *JAMA*. 2020;323(22):2301–2309.
 112. Kulesza M, Ramsey S, Brown R, Larimer M. Stigma among individuals with substance use disorders: Does it predict substance use, and does it diminish with treatment? *J Addict Behav Ther Rehabil*. 2014;3(1):1000115.
 113. Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration Center for Integrated Health Solutions. SBIRT: Screening, brief intervention, and referral to treatment: Opportunities for implementation and points for consideration. 2011 [cited 2019 Aug]. Available from: https://www.integration.samhsa.gov/sbirt_issue_brief.pdf
 114. Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: Comparison at intake and 6 months later. *Drug Alcohol Depend*. 2009;99(1–3):280–295.
 115. Gormican EK, Hussein ZS. SBIRT (Screening, Brief Intervention, and Referral to Treatment) among trauma patients: A review of the inpatient process and patient experience. *J Trauma Nurs*. 2017;24(1):42–45.
 116. Pringle JL, Kelley DK, Kearney SM, et al. Screening, brief intervention, and referral to treatment in the emergency department: An examination of health care utilization and costs. *Med Care*. 2018;56(2):146–152.
 117. Saitz R, Palfai TPA, Cheng DM, et al. Screening and brief intervention for drug use in primary care: the ASPIRE randomized clinical trial. *JAMA*. 2014;312(5):502–513.
 118. Bogenschutz MP, Donovan DM, Mandler RN, et al. Brief intervention for patients with problematic drug use presenting in emergency departments: A randomized clinical trial. *JAMA Intern Med*. 2014;174(11):1736–1745.
 119. Lindley B, Cox N, Cochran G. Screening tools for detecting problematic opioid use and potential application to community pharmacy practice: A review. *Integr Pharm Res Pract*. 2019;8:85–96.
 120. Cochran G, Field C, Karp J, et al. A community pharmacy intervention for opioid medication misuse: A pilot randomized clinical trial. *J Am Pharm Assoc*. 2018;58(4):395–403.
 121. Shonesy BC, Williams D, Simmons D, Dorval E, Gitlow S, Gustin RM. Screening, brief intervention, and referral to treatment in a retail

- pharmacy setting: The pharmacist's role in identifying and addressing risk of substance use disorder. *J Addict Med.* 2019;13(5):403–407.
122. Alliance for Addiction Payment Reform. Addiction recovery medical home alternative payment model. 2019 [cited 2020 Jun]. Available from: <https://www.incentivizerecovery.org/>
 123. Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. *Drug Alcohol Depend.* 2019;197:78–82.
 124. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. *J Addict Med.* 2015;9(5):358–367.
 125. Larochelle MR, Bernstein R, Bernson D, et al. Touchpoints—Opportunities to predict and prevent opioid overdose: A cohort study. *Drug Alcohol Depend.* 2019;204:107537.
 126. Substance Abuse and Mental Health Services Administration. *National survey of substance abuse treatment services (N-SSATS): 2017. Data on substance abuse treatment facilities.* Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018 [cited 2020 Mar]. Available from: https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/2017_NSSATS.pdf.
 127. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder. *Medications for opioid use disorder save lives.* Washington, DC: National Academies Press, 2019 [cited 2019 Aug]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK538936/>.
 128. Center for Behavioral Health Statistics and Quality. *2017 National survey on drug use and health: Detailed tables.* Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018 [cited 2019 Sept]. Available from: <https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHDetailedTabs2017/NSDUHDetailedTabs2017.pdf>.
 129. Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. *JAMA Netw Open.* 2020;3(2):e1920622.
 130. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. *BMJ.* 2017;357:j1550.
 131. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: The international experience. *Clin Infect Dis.* 2006;43(suppl 4):S197–S215.
 132. Winograd RP, Wood CA, Stringfellow EJ, et al. Implementation and evaluation of Missouri's medication first treatment approach for opioid use disorder in publicly-funded substance use treatment programs. *J Subst Abuse Treat.* 2020;108:55–64.
 133. Korthuis PT, McCarty D, Weimer M, et al. Primary care-based models for the treatment of opioid use disorder: A scoping review. *Ann Intern Med.* 2017;166(4):268–278.
 134. Lagisetty P, Klasa K, Bush C, Heisler M, Chopra V, Bohnert A. Primary care models for treating opioid use disorders: What actually works? A systematic review. *PLoS One.* 2017;12(10):e0186315.
 135. Hser Y-I, Evans E, Huang D, et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. *Addiction.* 2016;111(4):695–705.
 136. Clark RE, Baxter JD, Aweh G, O'Connell E, Fisher WH, Barton BA. Risk factors for relapse and higher costs among Medicaid members with opioid dependence or abuse: Opioid agonists, comorbidities, and treatment history. *J Subst Abuse Treat.* 2015;57:75–80.
 137. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. *Lancet.* 2003;361(9358):662–668.
 138. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst Rev.* 2014;2:CD002207.
 139. Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. *JAMA.* 2008;300(17):2003–2011.
 140. Green TC, Clarke J, Brinkley-Rubinstein L, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. *JAMA Psychiat.* 2018;75(4):405–407.
 141. Lee JD, Nunes EV, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial. *Lancet.* 2018;391(10118):309–318.
 142. Murphy SM, McCollister KE, Leff JA, et al. Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse. *Ann Intern Med.* 2019;170(2):90–98.
 143. Agrawal A, Lynskey MT. Are there genetic influences on addiction: Evidence from family, adoption and twin studies. *Addiction.* 2008;103(7):1069–1081.
 144. Raisch DW, Fudala PJ, Saxon AJ, et al. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/naloxone to patients with opioid dependence. *J Am Pharm Assoc.* 2005;45(1):23–32.
 145. Lo-Ciganic W-H, Gellad WF, Gordon AJ, et al. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. *Addiction.* 2016;111(5):892–902.
 146. Dick AW, Pacula RL, Gordon AJ, et al. Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002–11. *Health Aff.* 2015;34(6):1028–1034.
 147. H.R. 2482—116th Congress: Mainstreaming Addiction Treatment Act of 2019. 2019 [cited 2020 March]. Available from: <https://www.govtrack.us/congress/bills/116/hr2482>
 148. Jones CM, McCance-Katz EF. Characteristics and prescribing practices of clinicians recently waived to prescribe buprenorphine for the treatment of opioid use disorder. *Addiction.* 2019;114(3):471–482.
 149. Parrino M. *Using medication assisted treatment to treat opioid use disorder: Learning from past experience to guide policy.* New York: American Association for the Treatment of Opioid Dependence, Inc. (AATOD), 2019 [cited 2020 March]. Available from: <http://www.aatod.org/wp-content/uploads/2019/02/2019-Policy-Paper.pdf>.
 150. Stoller KB, Ann MC, Schorr A. Integrated service delivery models for opioid treatment programs in an era of increasing opioid addiction, health reform, and parity. 2016 [cited 2019 Aug]. Available from: <http://www.aatod.org/wp-content/uploads/2016/07/2nd-Whitepaper.pdf>
 151. Rawson RA. Vermont hub-and-spoke model of care for opioid use disorders: An evaluation. 2017 [cited 2020 Mar]. Available from: https://www.healthvermont.gov/sites/default/files/documents/pdf/ADAP_Hub_and_Spoke_Evaluation_2017_1.pdf
 152. Rawson RA, Rieckmann T, Cousins S, McCann M, Pearce R. Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system. *Prev Med.* 2019;27:105785.
 153. Luli AJ, Bounthavong M, Watanabe JH. Pharmacists on the front-line of solving a public health crisis: Increasing access to medications for opioid use disorder. *J Am Pharm Assoc.* 2020;60(2):297–303.
 154. D'Onofrio G, Chawarski MC, O'Connor PG, et al. Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: Outcomes during and after intervention. *J Gen Intern Med.* 2017;32(6):660–666.

155. Kaucher KA, Caruso EH, Sungar G, et al. Evaluation of an emergency department buprenorphine induction and medication-assisted treatment referral program. *Am J Emerg Med.* 2019;30:158373.
156. Englander H, Dobbertin K, Lind BK, et al. Inpatient addiction medicine consultation and post-hospital substance use disorder treatment engagement: A propensity-matched analysis. *J Gen Intern Med.* 2019;34(12):2796–2803.
157. Priest KC, McCarty D. Role of the hospital in the 21st century opioid overdose epidemic: The addiction medicine consult service. *J Addict Med.* 2019;13(2):104–112.
158. Wen H, Druss BG, Cummings JR. Effect of Medicaid expansions on health insurance coverage and access to care among low-income adults with behavioral health conditions. *Health Serv Res.* 2015;50(6):1787–1809.
159. ASHP. Statement on the pharmacist's role in substance abuse prevention, education, and assistance. *Am J Health-Syst Pharm.* 2016;73(9):e267–e270.
160. Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder—And its treatment. *JAMA.* 2014;311(14):1393–1394.
161. Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. *JAMA.* 2016;316(11):1211–1212.
162. Hutchinson E, Catlin M, Andrilla CHA, Baldwin L-M, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. *Ann Fam Med.* 2014;12(2):128–133.
163. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database Syst Rev.* 2002;4(2):CD002209. <https://doi.org/10.1002/14651858.CD002209>
164. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. *Arch Gen Psychiatry.* 2011;68(12):1238–1246.
165. Andrilla CHA, Coulthard C, Larson EH. Barriers rural physicians face prescribing buprenorphine for opioid use disorder. *Ann Fam Med.* 2017;15(4):359–362.
166. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. *JAMA.* 2000;284(13):1689–1695.
167. Duffy P, Mackridge AJ. Use and diversion of illicit methadone—Under what circumstances does it occur, and potential risks associated with continued use of other substances. *J Subst Use.* 2014;19(1–2):48–55.
168. Schuman-Olivier Z, Albanese M, Nelson SE, et al. Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers. *J Subst Abuse Treat.* 2010;39(1):41–50.
169. Mark TL, Parish W, Zarkin GA. Association between Medicare and FDA policies and prior authorization requirements for buprenorphine products in Medicare part D plans. *JAMA.* 2019;322(2):166–167.
170. Saloner B, Levin J, Chang H-Y, Jones C, Alexander GC. Changes in buprenorphine-naloxone and opioid pain reliever prescriptions after the affordable care act Medicaid expansion. *JAMA Netw Open.* 2018;1(4):e181588.
171. DiPaula BA, Menachery E. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients. *J Am Pharm Assoc.* 2015;55(2):187–192.
172. Drug Enforcement Administration. Mid-level practitioners authorization by state. 2019 [cited 2019 Oct]. Available from: https://www.deadiversion.usdoj.gov/drugreg/practioners/mlp_by_state.pdf
173. California Health & Safety Code. Article 2. Treatment of addicts for addiction. Section 11215. 1995.
174. California State Board of Pharmacy. The script: Board adopts policy on pharmacists and MAT. 2019 [cited 2019 Sept]. Available from: https://www.pharmacy.ca.gov/publications/19_mar_script.pdf
175. McBournie A, Duncan A, Connolly E, Rising J. Methadone barriers persist, despite decades of evidence. *Health Affairs Blog.* 2019 [cited 2020 March]. Available from: <https://www.healthaffairs.org/doi/10.1377/hblog20190920.981503/full/>
176. Joudrey PJ, Chadi N, Roy P, et al. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study. *Drug Alcohol Depend.* 2020;27:107968.
177. Goffman E. *Stigma: Notes on the management of a spoiled identity.* Englewood Cliffs, NJ: Prentice-Hall, 1963.
178. Pescosolido BA, Martin JK. The stigma complex. *Annu Rev Sociol.* 2015;41:87–116.
179. Kennedy-Hendricks A, Barry CL, Gollust SE, Ensminger ME, Chisolm MS, McGinty EE. Social stigma toward persons with prescription opioid use disorder: Associations with public support for punitive and public health-oriented policies. *Psychiatr Serv.* 2017;68(5):462–469.
180. Barry CL, McGinty EE, Pescosolido BA, Goldman HH. Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness. *Psychiatr Serv.* 2014;65(10):1269–1272.
181. Legal Action Center. State Medicaid programs should follow the "Medicare Model". 2019 [cited 2019 Sept]. Available from: <https://lac.org/wp-content/uploads/2019/07/access-to-meds-in-medicaid-eweber-FINAL-070919.pdf>
182. Narcotics Anonymous World Services. *Narcotics Anonymous and persons receiving medication-assisted treatment.* Chatsworth, CA: NA World Services, Inc., 2016 [cited 2019 Sept]. Available from: https://www.na.org/admin/include/spaw2/uploads/pdf/pr/2306_NA_PRMAT_1021.pdf.
183. McGinty EE, Stone EM, Kennedy-Hendricks A, Barry CL. Stigmatizing language in news media coverage of the opioid epidemic: Implications for public health. *Prev Med.* 2019;124:110–114.
184. Botticelli MP, Koh HK. Changing the language of addiction. *JAMA.* 2016;316(13):1361–1362.
185. Ashford RD, Brown AM, Curtis B. Substance use, recovery, and linguistics: The impact of word choice on explicit and implicit bias. *Drug Alcohol Depend.* 2018;189:131–138.
186. van Boekel LC, Brouwers EPM, van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review. *Drug Alcohol Depend.* 2013;131(1):23–35.
187. Collins AB, Bluthenthal RN, Boyd J, McNeil R. Harnessing the language of overdose prevention to advance evidence-based responses to the opioid crisis. *Int J Drug Policy.* 2018;55:77–79.
188. The American Pharmacists Association. Oath of a pharmacist. 1994 [cited 2019 Aug]. Available from: <http://www.pharmacist.com/oath-pharmacist>
189. Bratberg J. Pharmacy: Addressing substance use in the 21st century. *Subst Abuse.* 2019;40(4):421–434.
190. American Association of Colleges of Pharmacy. Academic pharmacy's role in increasing knowledge, access to resources and evidence to combat the opioid epidemic, executive summary. 2019 [cited 2019 Aug]. Available from: <https://www.aacp.org/opioid>
191. Lee M, Saseen JJ, Beckman E, et al. Expanding the pharmacist's scope of practice at the state level: Support for board certification within the credentialing process. *J Am Coll Clin Pharm.* 2019;2(6):694–701.
192. American Society of Health-System Pharmacists Online residency directory. 2019 [cited 2019 Nov]. Available from: <https://accreditation.ashp.org/directory/#/program/residency>
193. Centers for Medicare & Medicaid Services. Trump administration takes steps to expand access to treatment for opioid use disorder. 2019 [cited 2019 Nov]. Available from: <https://www.cms.gov/>

- newsroom/press-releases/trump-administration-takes-steps-expand-access-treatment-opioid-use-disorder
194. Nagel, LM. Drug enforcement administration emergency narcotic addiction treatment. 2002 [cited 2020 Sept]. Available from: https://www.deadiversion.usdoj.gov/pubs/advisories/emerg_treat.htm
195. Substance Abuse and Mental Health Services Administration. *Medications for opioid use disorder. Treatment improvement protocol (TIP) series 63, full document. HHS publication no. (SMA) 18-5063FULLDOC*. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018 [cited 2020 Mar]. Available from: <https://store.samhsa.gov/product/SMA18-5063FULLDOC>.
196. Cueva JP, Roche C, Ostovar M, et al. C7 β -methyl analogues of the orvinols: The discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors. *J Med Chem*. 2015;10:4242–4249.
197. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. *Pain Physician*. 2008;2(suppl):S133–S153.

How to cite this article: Coon SA, Hill LG, Hutchison RW, et al. Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy. *J Am Coll Clin Pharm*. 2020;3:1493–1513. <https://doi.org/10.1002/jac5.1331>